SI2762163T1 - Postopki za dajanje cepiva - Google Patents

Postopki za dajanje cepiva Download PDF

Info

Publication number
SI2762163T1
SI2762163T1 SI200732011T SI200732011T SI2762163T1 SI 2762163 T1 SI2762163 T1 SI 2762163T1 SI 200732011 T SI200732011 T SI 200732011T SI 200732011 T SI200732011 T SI 200732011T SI 2762163 T1 SI2762163 T1 SI 2762163T1
Authority
SI
Slovenia
Prior art keywords
tcid50
dose
vaccine
dog
virus
Prior art date
Application number
SI200732011T
Other languages
English (en)
Inventor
John David Haworth
Cassius Mcallister Tucker
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39609100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2762163(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of SI2762163T1 publication Critical patent/SI2762163T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18471—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (8)

  1. Postopki za dajanje cepiva Patentni zahtevki
    1. Cepivo za uporabo pri postopku cepljenja psa proti naslednjim pasjim boleznim: 1) kužnemu hepatitisu psov, ki ga povzroča CAV-1; 2) pasji kugi, ki jo povzroča virus pasje kuge (CDV); in 3) pasjemu parvovirusnemu enteritisu, ki ga povzroča pasji parvovirus (CPV); pri čemer cepivo obsega naslednje spremenjene žive viruse: 1) pasji adenovirus tipa 2 (CAV-2); 2) virus pasje kuge (CDV); in 3) pasji parvovirus (CPV); označeno s tem, da se cepivo daje subkutano v prvem odmerku, peroralno v drugem odmerku, ki se daje od 7 do vključno 35 dni po prvem odmerku, peroralno po izbiri v tretjem odmerku, ki se daje od 7 do vključno 35 dni po drugem odmerku, in peroralno v enem ali več letnih odmerkih eno leto po prvem odmerku ali od štiri tedne pred enoletno obletnico prvega odmerka do štiri tedne po njej.
  2. 2. Cepivo za uporabo po zahtevku 1, pri čemer se letni odmerki, ki se dajejo po omenjenem letnem odmerku, dajejo ponavljaje eno leto takoj po prejšnjem letnem odmerku.
  3. 3. Cepivo za uporabo po zahtevku 1, pri čemer se da tretji odmerek.
  4. 4. Cepivo za uporabo po katerem koli od predhodnih zahtevkov, pri čemer je velikost odmerka od 0,1 mL do vključno 5 mL.
  5. 5. Cepivo za uporabo po katerem koli od predhodnih zahtevkov, pri čemer pasje bolezni dodatno obsegajo pasjo parainfluenco, ki jo povzroča virus pasje parainfiuence (CPI) in cepivo dodatno obsega spremenjeni živi virus pasje parainfiuence (CPI).
  6. 6. Cepivo za uporabo po katerem koli od predhodnih zahtevkov, pri čemer: (a) so spremenjeni živi virusi prisotni v naslednjih območjih količine: za virus CD, od 102 TCIDso do vključno 108 TCIDso; za CAV-2, od 102 TCIDso do vključno 108 TCIDso,; za CPV, od 103 TCID50 do vključno 1010 TCID50; in za virus CPI, od 103 TCID50 do vključno 101°TCID5o; (b) so spremenjeni živi virusi prisotni v naslednjih območjih količine: za virus CD, od 103 TCID50 do vključno 106 TCID50; za CAV-2, od 103 TCID50 do vključno 106 TCID50; za CPV, od 106 TCID50 do vključno 109 TCID50: in za virus CPI, od 105 TCID50 do vključno 109 TCID50; ali (c) so spremenjeni živi virusi prisotni v naslednjih območjih količine: za virus CD, od 104 TCID50 do vključno 105 TCID50; za CAV-2, od 104 TCID50 do vključno 105 TCID50; za CPV, od 107 TCID50 do vključno 10® TCID50; in za virus CPI, od 106 TCID50 do vključno 10® TCID50.
  7. 7. Cepivo za uporabo po katerem koli od predhodnih zahtevkov, pri čemer se drugi odmerek daje 17-25 dni po prvem odmerku.
  8. 8. Cepivo za uporabo po katerem koli od predhodnih zahtevkov, pri čemer se tretji odmerek daje 17-25 dni po drugem odmerku.
SI200732011T 2006-12-27 2007-11-23 Postopki za dajanje cepiva SI2762163T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87732206P 2006-12-27 2006-12-27
EP14166489.6A EP2762163B1 (en) 2006-12-27 2007-11-23 Methods of vaccine administration

Publications (1)

Publication Number Publication Date
SI2762163T1 true SI2762163T1 (sl) 2018-05-31

Family

ID=39609100

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200732011T SI2762163T1 (sl) 2006-12-27 2007-11-23 Postopki za dajanje cepiva

Country Status (25)

Country Link
US (4) US20100028379A1 (sl)
EP (5) EP3300743B1 (sl)
JP (1) JP5762664B2 (sl)
KR (1) KR101099883B1 (sl)
CN (1) CN101573137B (sl)
AR (1) AR064530A1 (sl)
AU (1) AU2007343130C1 (sl)
BR (1) BRPI0720667A8 (sl)
CA (1) CA2674026C (sl)
CY (1) CY1120015T1 (sl)
DK (2) DK2762163T3 (sl)
ES (2) ES2660035T3 (sl)
FI (1) FI3300743T3 (sl)
HK (4) HK1134243A1 (sl)
HU (2) HUE036174T2 (sl)
LT (1) LT2762163T (sl)
MX (1) MX2009007087A (sl)
NZ (1) NZ577855A (sl)
PL (2) PL3300743T3 (sl)
PT (1) PT2762163T (sl)
SI (1) SI2762163T1 (sl)
TR (1) TR201802917T4 (sl)
TW (1) TW200833354A (sl)
WO (1) WO2008084294A2 (sl)
ZA (1) ZA200904756B (sl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
EP3300743B1 (en) * 2006-12-27 2023-06-14 Zoetis Services LLC Methods of vaccine administration
US8877201B2 (en) 2007-10-25 2014-11-04 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
JP2012533557A (ja) * 2009-07-17 2012-12-27 ザ・ボード・オブ・リージェンツ・フォー・オクラホマ・ステート・ユニバーシティ 舌上ワクチン及びアプリケーター
US20110229516A1 (en) * 2010-03-18 2011-09-22 The Clorox Company Adjuvant phase inversion concentrated nanoemulsion compositions
CN101914502B (zh) * 2010-07-30 2012-01-11 中国农业科学院哈尔滨兽医研究所 Ⅰ型犬腺病毒弱毒疫苗株及其应用
US20120107354A1 (en) * 2010-10-30 2012-05-03 George Dacai Liu Viral vaccine and process for preparing the same
JP6034797B2 (ja) 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 凍結乾燥されたウイルス製剤
JP6034798B2 (ja) 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤
US9359627B2 (en) 2011-03-17 2016-06-07 National University Corporation Mie University Antibody production method
JP6313752B2 (ja) * 2012-05-31 2018-04-18 ゾエティス・エルエルシー Ｂ．ブロンキセプチカ（Ｂ．Ｂｒｏｎｃｈｉｓｅｐｔｉｃａ）感染から保護するためのイヌ呼吸器コロナウイルスでのワクチン接種
CZ307883B6 (cs) * 2013-01-29 2019-07-24 Bioveta, A.S. Multivalentní vakcína k imunoprofylaxi infekčních onemocnění psů
CN107320720A (zh) * 2016-04-29 2017-11-07 普莱柯生物工程股份有限公司 一种疫苗组合物、试剂盒及应用
CN106591242B (zh) * 2016-11-18 2019-08-30 北京世纪元亨动物防疫技术有限公司 一株犬细小病毒毒株cpv-yh及其应用
AU2018219437B2 (en) * 2017-02-13 2023-03-02 Boehringer lngelheim Vetmedica GMBH Liquid applicator for delivering vaccines
GB201806460D0 (en) * 2018-04-20 2018-06-06 Secr Defence Pharmaceutical compositions and associated kits
WO2024121203A1 (en) * 2022-12-07 2024-06-13 Intervet International B.V. Vaccine for vaccinating a canine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5013663A (en) * 1983-06-15 1991-05-07 American Home Products Corporation Canine corona virus vaccine
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
DE3526809A1 (de) * 1985-07-26 1987-04-02 Behringwerke Ag Tollwut-lebendimpfstoff
DE3775783D1 (de) 1986-01-14 1992-02-20 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US5019388A (en) * 1986-10-14 1991-05-28 Norden Laboratories Inc. Bordetella bronchiseptica vaccine
US4990367A (en) * 1987-03-09 1991-02-05 Diamond Scientific Company Canine distemper virus vaccine
US5000951A (en) * 1987-03-09 1991-03-19 Diamond Scientific Company Multivalent canine distemper virus vaccine
FR2652501B1 (fr) 1989-10-02 1992-01-10 Rhone Merieux Elements therapeutiques pour l'administration orale d'un medicament aux animaux et procede de fabrication.
US5178862A (en) * 1989-12-01 1993-01-12 Parhelion Corporation Canine distemper virus vaccine and method of preparation
US5757063A (en) * 1994-03-25 1998-05-26 Kabushiki Kaisha Toshiba Semiconductor device having an extrinsic gettering film
CN1117081A (zh) * 1995-03-16 1996-02-21 高云 犬瘟热狂犬病细小病毒三联活疫苗、毒种及制造方法
CN1137347A (zh) * 1995-06-22 1996-12-11 中国人民解放军第四军医大学 犬五联(犬狂犬、犬瘟热、犬细小病毒、犬腺病毒2型、犬副流感)活疫苗
WO1998018453A1 (en) * 1996-10-28 1998-05-07 Pfizer Inc. Oral vaccines for young animals with an enteric coating
US5884583A (en) 1997-03-28 1999-03-23 Rhone Merieux, Inc. Field bag boost vaccination delivery system
AU3613001A (en) 2000-02-12 2001-08-20 In-Sik Chung Production method of recombinant rotavirus structural proteins and vaccine composition
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
US20030129161A1 (en) 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
WO2004067031A1 (en) * 2003-01-29 2004-08-12 Pfizer Products Inc. Canine vaccines against bordetella bronchiseptica
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
EP1778281A4 (en) 2004-06-21 2010-01-20 Merial Ltd VACCINATION OF SKUNKS AND / OR MUNGOS AGAINST TOLLWUT
US8821893B2 (en) 2004-07-02 2014-09-02 Bio Peptides, Corp. Oral vaccine for Borrelia
CA2604488A1 (en) * 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
KR20110126726A (ko) * 2005-10-07 2011-11-23 화이자 프로덕츠 인코포레이티드 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법
EP3300743B1 (en) * 2006-12-27 2023-06-14 Zoetis Services LLC Methods of vaccine administration

Also Published As

Publication number Publication date
HK1134243A1 (en) 2010-04-23
PL3300743T3 (pl) 2023-09-11
JP5762664B2 (ja) 2015-08-12
HUE062920T2 (hu) 2023-12-28
HK1249031A1 (zh) 2018-10-26
TR201802917T4 (tr) 2018-03-21
EP2129392A2 (en) 2009-12-09
HK1200374A1 (en) 2015-08-07
EP3300743A1 (en) 2018-04-04
AR064530A1 (es) 2009-04-08
CA2674026A1 (en) 2008-07-17
WO2008084294A3 (en) 2008-12-31
MX2009007087A (es) 2009-08-12
BRPI0720667A2 (pt) 2014-01-14
US11524068B2 (en) 2022-12-13
PT2762163T (pt) 2018-02-22
US20100028379A1 (en) 2010-02-04
TW200833354A (en) 2008-08-16
BRPI0720667A8 (pt) 2017-04-25
DK3300743T3 (da) 2023-07-24
KR101099883B1 (ko) 2011-12-28
EP4233899A3 (en) 2023-11-08
EP4233899A2 (en) 2023-08-30
US11524067B2 (en) 2022-12-13
US20150182619A1 (en) 2015-07-02
ZA200904756B (en) 2010-05-26
EP2762163B1 (en) 2018-01-03
HUE036174T2 (hu) 2018-06-28
EP3300743B1 (en) 2023-06-14
EP2762162A1 (en) 2014-08-06
CN101573137B (zh) 2014-05-14
AU2007343130B2 (en) 2012-12-20
ES2660035T3 (es) 2018-03-20
US20200316192A1 (en) 2020-10-08
NZ577855A (en) 2012-07-27
EP2762163A1 (en) 2014-08-06
US20230078668A1 (en) 2023-03-16
AU2007343130C1 (en) 2017-11-09
DK2762163T3 (en) 2018-02-12
PL2762163T3 (pl) 2018-05-30
CY1120015T1 (el) 2018-12-12
CA2674026C (en) 2018-08-21
ES2951660T3 (es) 2023-10-24
JP2008169207A (ja) 2008-07-24
KR20090094393A (ko) 2009-09-04
EP2129392B1 (en) 2013-07-31
LT2762163T (lt) 2018-02-26
FI3300743T3 (fi) 2023-08-11
HK1200372A1 (en) 2015-08-07
WO2008084294A2 (en) 2008-07-17
CN101573137A (zh) 2009-11-04
AU2007343130A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
SI2762163T1 (sl) Postopki za dajanje cepiva
RU2400248C2 (ru) ПОЛИВАЛЕНТНЫЕ ВАКЦИНЫ ДЛЯ СОБАК ПРОТИВ Leptospira bratislava И ДРУГИХ ПАТОГЕНОВ
Polack Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple
HRP20050192B1 (hr) Cjepivo za infekcije dišnog i spolnog sustava kod goveda
MX2009004223A (es) Protocolo de inmunizacion contra los 4 serotipos del dengue.
CA2400468A1 (en) Proteosome influenza vaccine
JP2009518410A5 (sl)
Kim et al. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model
KR20110053345A (ko) 인플루엔자 백신
Kopecky-Bromberg et al. Recombinant vectors as influenza vaccines
See et al. Efficacy of a polyvalent inactivated-virus vaccine in protecting mice from infection with clinical strains of group B coxsackieviruses
Edington et al. One way protection between equid herpesvirus 1 and 4 in vivo
JP2023091085A (ja) 粘膜アジュバント
JP2013540825A (ja) ウィルスワクチン及びその調製方法
BRPI0508660A (pt) composição de vacina eficaz na prevenção ou melhora da infecção por vìrus da doença bursal infecciosa; composição de vacina; isolado antigênico do vìrus da doença bursal infecciosa; e método para induzir proteção contra infecção do vìrus da doença bursal infecciosa
JP2521226B2 (ja) 犬用多種混合ワクチン
De Clercq et al. Simultaneous vaccination of piglets against foot-and-mouth disease and classical swine fever
John Pólio eradication & índia–bringing science into public health
Keles et al. Vaccination with glutaraldehyde-fixed bovine respiratory syncytial virus (BRSV)-infected cells stimulates a better immune response in lambs than vaccination with heat-inactivated cell-free BRSV
Kamaraj et al. Validation of betapropiolactone (BPL) as an inactivant for infectious bovine rhinotracheitis (IBR) virus
JP2020536107A5 (sl)
Moura et al. In ovo vaccine against infectious bursal disease
RU2013135887A (ru) Композиции для комплекса респираторных заболеваний собак
EP2579884B1 (en) Anti-tumor composition
Tregnaghi et al. Oral Human Rotavirus Vaccine RIX4414 (Rotarix™) Co-administered with Routine EPI Vaccinations Including Oral Polio Vaccine (OPV) Is Highly Efficacious in Latin-America